Skip to content

Clinical Trial to Reduce Perinatal Intimate Partner Violence

Novel Doula Intervention to Leverage Clinic-community Connections to Support Perinatal Intimate Partner Violence Survivors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07165860
Enrollment
250
Registered
2025-09-10
Start date
2025-11-01
Completion date
2029-05-01
Last updated
2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Domestic Violence, Perinatal Problems

Keywords

intimate partner violence, perinatal health, doula

Brief summary

This is a two-armed, fully powered hybrid type 1 trial to test the effectiveness of a doula intervention compared with an active control in reducing intimate partner violence (IPV) among perinatal IPV survivors

Detailed description

The study team will complete a 2-arm randomized clinical trial to test the effectiveness of IPV-trained doulas compared with an active control in reducing IPV among perinatal IPV survivors. Participants randomized into doula group will be paired community doula who will provide full-spectrum doula services prenatally (22 weeks gestation), through the birthing period, to early postpartum (6 months total). Participants randomized to the active two structured intakes from a victim services agency. Participants will be recruited from their prenatal visit at 1 of 3 sites with 125 perinatal people randomized to the doula group and 125 randomized to active control (N=250). The primary outcome is change in IPV across a range coercive behaviors from baseline to 12-months post enrollment. Secondary outcomes include change in cannabis and tobacco use, as well as depressive symptoms, anxiety, and unmet basic needs. The study will also be assessing changes in intermediate outcomes, including resource utilization, trust of doulas and IPV advocates, parenting stress, safety-related empowerment, and social support. Measures will be completed at enrollment, and then 3-, 6-, and 12-months post-enrollment. In Aim 2, the study team will be assessing potential mediators and moderators driving intervention effects and in Aim 3, collecting information about implementation outcomes.

Interventions

BEHAVIORALDoulas

The intervention will be pairing intimate partner violence survivors with a trained doula

BEHAVIORALThrive

The active control arm will include pairing intimate partner violence survivors with IPV advocates

Sponsors

University of Pittsburgh
Lead SponsorOTHER
National Institute of Nursing Research (NINR)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Masking description

The trial will be blinded to the investigators and participants will be unblinded if a participant is experiencing distress or needs support from the primary investigator

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Perinatal IPV survivors are eligible if they: * 1\) feel comfortable completing the study in Spanish or English * 2\) are age 18 or older * 3\) are no more than 24 weeks 6 days gestation (note: participants enrolled earliest at 18 weeks, baseline at 22 weeks with a 3 week window) * 4\) identify as an IPV survivor by answering affirmatively to a definition of experiencing IPV * 5\) live within a 50 mile radius of Pittsburgh, Pennsylvania * 6\) able to provide safe and complete contact information or take a study cell phone

Exclusion criteria

* Unable to consent * Do not meet inclusion criteria * Cannot provide safe contact information or take a study cell phone * Incarcerated

Design outcomes

Primary

MeasureTime frameDescription
Perinatal physical, sexual, or emotional abuse (past 3 months)baseline, 3 months, 6 months, 12 months15 item Composite Abuse Scale Short form, scale is 0 to 5 and 15 items are added for a summary score, higher number means more IPV
Substance use coercion (past 3 month)baseline, 3 months, 6 months, and 12 months5 item measure answer choices and yes/no
Mental health coercion (past 3 month)baseline, 3 months, 6 months, and 12 months5 item mental health coercion survey with yes and no answer choices
Economic Abuse (past 3 month)baseline, 3 month, 6 months, and 12 months12 item Revised Scale of Economic Abuse (answer choices yes or no), more yes responses means more experiences of economic abuse
Reproductive Coercion (past 3 months)baseline, 3 months, 6 months, and 12 months9 item reproductive coercion scale (answer choices yes/no). More yes responses means more experiences of reproductive coercion
Sleep coercion (past 3 months)baseline, 3 months, 6 months, and 12 months1 item sleep coercion measure (investigator developed, yes/no)
Past 3-month Digital coercionbaseline, 3, 6, and 12 months4 item measure on digital coercion, scored yes or no
Past 3 month Health-related coercionbaseline, 3, 6, and 12 months3 item measure focused on coercion experienced related to healthcare, health, or medical choices, score yes/no

Secondary

MeasureTime frameDescription
Substance usebaseline4 item validated measure to assess substance use during pregnancy
Tobacco usebaseline, 3 months, 6 months, 12 monthsType, frequency, use currently and before pregnancy (4 items)
Depressive symptomsbaseline, 3 months, 6 months, 12 months10 item Edinburgh Postnatal Depression Scale; α=0.87, summary scale and mean, higher score means more depression. Scale ranges from 0 to 30
Anxietybaseline, 3 months, 6 months, and 12 months7 item validated GAD-7, scores Likert 0 to 3, added up for summary scale, higher score means more anxiety. Scale ranges from 0 to 21
Unmet basic needs (financial, food, and housing insecurity)Baseline, 12 months5 item investigator developed scale on food, housing, and utilities insecurity. Answer choices yes or no, more yes choices chosen means more unmet basic needs
Past 3-month substance use6 months, 12 monthsSubstances used in the past 3 months, first yes/no and then type of substance

Countries

United States

Contacts

CONTACTMaya Ragavan
ragavanm@chp.edu4126926545
PRINCIPAL_INVESTIGATORMaya I Ragavan

University of Pittsburgh

PRINCIPAL_INVESTIGATORDara Mendez

University of Pittsburgh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026